Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir
combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …

Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised
individuals receiving remdesivir. We describe an immunocompromised patient who was …

The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC), which
contains a heavily mutated spike protein capable of escaping preexisting immunity …

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods …

Dear Editor, The ongoing SARS-CoV-2 pandemic continues to be a significant threat to
global health. First reported in November 2021, the Omicron variant (B. 1.1. 529) is more …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …